Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. September 2024 08:15 ET | Quelle: Senti Biosciences, Inc.

Senti Bio to Participate in Upcoming Investor Conferences

Senti Bio will participate in two upcoming investor conferences in September.
13. August 2024 16:05 ET | Quelle: Senti Biosciences, Inc.

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
09. Mai 2024 16:05 ET | Quelle: Senti Biosciences, Inc.

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
15. Juni 2020 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
11. Dezember 2019 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...